These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1365453)

  • 1. Cholecystokinin receptors in relation to brain dopaminergic pathways.
    Woodruff GN
    Neurochem Int; 1992 Mar; 20 Suppl():339S-343S. PubMed ID: 1365453
    [No Abstract]   [Full Text] [Related]  

  • 2. Ionic mechanisms underlying cholecystokinin action in rat brain.
    Boden P; Woodruff GN
    Ann N Y Acad Sci; 1994 Mar; 713():129-37. PubMed ID: 7910440
    [No Abstract]   [Full Text] [Related]  

  • 3. Possible involvement of the CCK receptor in the benzodiazepine antagonism to CCK in the mouse brain.
    Sugaya K; Matsuda I; Kubota K
    Jpn J Pharmacol; 1987 Jan; 43(1):67-71. PubMed ID: 2883334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CCK, schizophrenia, and anxiety. CCK-B antagonists inhibit the activity of brain dopamine neurons.
    Rasmussen K
    Ann N Y Acad Sci; 1994 Mar; 713():300-11. PubMed ID: 8185172
    [No Abstract]   [Full Text] [Related]  

  • 5. Evidence that type A CCK receptors facilitate dopamine efflux in rat brain.
    Vickroy TW; Bianchi BR; Kerwin JF; Kopecka H; Nadzan AM
    Eur J Pharmacol; 1988 Aug; 152(3):371-2. PubMed ID: 3220112
    [No Abstract]   [Full Text] [Related]  

  • 6. Analysis of strain difference in behavior to Cholecystokinin (CCK) receptor mediated drugs in PVG hooded and Sprague-Dawley rats using elevated plus-maze test apparatus.
    Farook JM; Zhu YZ; Wang Q; Moochhala SM; Lee L; Wong PT
    Neurosci Lett; 2004 Apr; 358(3):215-9. PubMed ID: 15039119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain cholecystokinin receptors and satiety.
    Nutr Rev; 1990 Sep; 48(9):359-60. PubMed ID: 2096338
    [No Abstract]   [Full Text] [Related]  

  • 8. International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors.
    Noble F; Wank SA; Crawley JN; Bradwejn J; Seroogy KB; Hamon M; Roques BP
    Pharmacol Rev; 1999 Dec; 51(4):745-81. PubMed ID: 10581329
    [No Abstract]   [Full Text] [Related]  

  • 9. New virginiamycin M1 derivatives: synthesis, cholecystokinin binding inhibitory and antimicrobial properties.
    Lam YK; Dai P; Zink DL; Smith AJ; Lee NW; Freedman S; Salvatore MJ
    J Antibiot (Tokyo); 1993 Apr; 46(4):623-30. PubMed ID: 8501005
    [No Abstract]   [Full Text] [Related]  

  • 10. Cholecystokinin and cholecystokinin receptors.
    Miyasaka K; Funakoshi A
    J Gastroenterol; 2003; 38(1):1-13. PubMed ID: 12560916
    [No Abstract]   [Full Text] [Related]  

  • 11. [Involvement of the neuropeptide cholecystokinin in the mechanisms of regulation of emotions and craving].
    Anokhina IP; Proskuriakova TV
    Vestn Ross Akad Med Nauk; 2002; (6):36-40. PubMed ID: 12116760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution of cholecystokinin receptors in the bovine brain: a quantitative autoradiographic study.
    Morency MA; Quirion R; Mishra RK
    Neuroscience; 1994 Sep; 62(1):307-16. PubMed ID: 7816208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for cholecystokinin receptor and intracellular signal transduction in relation to amylase secretion.
    Kamiya H
    Adv Exp Med Biol; 1988; 236():95-109. PubMed ID: 2467534
    [No Abstract]   [Full Text] [Related]  

  • 14. Therapeutic potential of cholecystokinin receptor antagonists in CNS disorders.
    Schiantarelli P
    Pharmacol Res; 1993; 28(1):1-9. PubMed ID: 8234141
    [No Abstract]   [Full Text] [Related]  

  • 15. Cholecystokinin and gastrin receptors.
    Dufresne M; Seva C; Fourmy D
    Physiol Rev; 2006 Jul; 86(3):805-47. PubMed ID: 16816139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain CCK-B receptors mediate the suppression of dopamine release by cholecystokinin.
    Altar CA; Boyar WC
    Brain Res; 1989 Apr; 483(2):321-6. PubMed ID: 2706523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies.
    Harro J
    Amino Acids; 2006 Oct; 31(3):215-30. PubMed ID: 16738800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholecystokinin receptor antagonists: a review.
    Silverman MA; Greenberg RE; Bank S
    Am J Gastroenterol; 1987 Aug; 82(8):703-8. PubMed ID: 3300275
    [No Abstract]   [Full Text] [Related]  

  • 19. Mutant mice lacking the cholecystokinin2 receptor show a dopamine-dependent hyperactivity and a behavioral sensitization to morphine.
    Daugé V; Beslot F; Matsui T; Roques BP
    Neurosci Lett; 2001 Jun; 306(1-2):41-4. PubMed ID: 11403953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postponement of satiety by blockade of brain cholecystokinin (CCK-B) receptors.
    Dourish CT; Rycroft W; Iversen SD
    Science; 1989 Sep; 245(4925):1509-11. PubMed ID: 2781294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.